FindTrial
Sign In

ATLCAR.CD30 cells

BIOLOGICAL3 trials

Sponsors

UNC Lineberger Comprehensive Cancer Center

Conditions

Germ Cell TumorHodgkin DiseaseImmune System DiseasesImmunoproliferative DisordersLymphatic DiseasesLymphomaLymphoma, Non-HodgkinLymphoproliferative Disorders

Phase 1

Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
Active, not recruitingNCT02663297
UNC Lineberger Comprehensive Cancer CenterHodgkin Disease, Immune System Diseases, Immunoproliferative Disorders +6
Start: 2016-06-07End: 2037-01-01Updated: 2026-06-09
Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL
Active, not recruitingNCT02690545
UNC Lineberger Comprehensive Cancer CenterImmune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases +5
Start: 2016-08-26End: 2039-11-04Updated: 2026-07-07

Phase 2

CD30 CAR for CD30+ NSGCT
CompletedNCT05634785
UNC Lineberger Comprehensive Cancer CenterGerm Cell Tumor, Nonseminomatous Germ Cell Tumor
Start: 2022-12-09End: 2025-12-18Updated: 2026-07-07

Related Papers

Patient-reported outcomes in CD30-directed CAR-T cells against relapsed/refractory CD30+ lymphomas
UNC Libraries2024-06-01
Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30<sup>+</sup> lymphoma: a phase 1 study.
2024-03-2817 citations
Patient-reported outcomes in CD30-directed CAR-T cells against relapsed/refractory CD30+ lymphomas
Journal for ImmunoTherapy of Cancer2023-08-0112 citations
Clinical Activity of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed Hodgkin Lymphoma
Blood2022-11-155 citations
Phase 1b/2 Study of Autologous CD30.CAR-T Cells in Combination with Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma after Failure of Frontline Therapy (ACTION)
Blood2022-11-153 citations
CD30-Directed Chimeric Antigen Receptor (CAR)-T Cells for Treatment of Hodgkin Lymphoma and Non-Hodgkin Lymphoma in Pediatric Patients
Blood2021-11-057 citations
Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma
Blood Advances2021-10-2045 citations
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma
UNC Libraries2021-05-071 citations
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma
Journal of Clinical Oncology2020-07-23366 citations
A phase 1b/2 study of CD30-specific chimeric antigen receptor T-cell (CAR-T) therapy in combination with bendamustine in patients with CD30+ Hodgkin and non-Hodgkin lymphoma.
Journal of Clinical Oncology2017-05-208 citations